Sturov N V, Popov S V, Mamporia N K, Mager A A
People's Friendship University of Russia.
Central Clinical Hospital of St. Alexy of the Moscow Patriarchate.
Ter Arkh. 2020 Dec 26;92(11):106-109. doi: 10.26442/00403660.2020.11.000581.
Selective inhibitors of sodium-glucose cotransporter belong to a new class of drugs for the treatment of type 2 diabetes mellitus. The mechanism of their action is based on insulin-independent reduction of glucose reabsorption in the proximal renal tubules, which leads to stimulation of its excretion in the urine and, accordingly, to a decrease in the concentration of glucose in the blood plasma. Drugs of this group demonstrate effectiveness in the treatment of type 2 diabetes, but their use may be associated with an increased frequency of urinary tract infections. Pharmacological glucosuria, which leads to a decrease in the concentration of glucose in the blood, creates the preconditions for the occurrence of urinary tract infections. Urinary tract and genital infections are the most common adverse events associated with the use of sodium-glucose cotransporter inhibitors. In the presented literature review for 20162019, the relationship between urinary tract infections in patients with type 2 diabetes mellitus and therapy with sodium-glucose cotransporter inhibitors was analyzed.
钠-葡萄糖协同转运蛋白选择性抑制剂属于一类用于治疗2型糖尿病的新型药物。它们的作用机制基于近端肾小管中葡萄糖重吸收的胰岛素非依赖性减少，这导致尿液中葡萄糖排泄增加，进而使血浆中葡萄糖浓度降低。该类药物在治疗2型糖尿病方面显示出有效性，但其使用可能与尿路感染频率增加有关。导致血液中葡萄糖浓度降低的药理性糖尿为尿路感染的发生创造了条件。尿路感染和生殖器感染是与使用钠-葡萄糖协同转运蛋白抑制剂相关的最常见不良事件。在本次针对2016年至2019年的文献综述中，分析了2型糖尿病患者尿路感染与钠-葡萄糖协同转运蛋白抑制剂治疗之间的关系。
